JPS6161818B2 - - Google Patents

Info

Publication number: JPS6161818B2
Authority: JP; Japan
Prior art keywords: weight; pharmaceutical composition; composition according; sprayable pharmaceutical; fatty
Prior art date: 1976-08-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP52102143A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5341417A (en

Inventor

Jakuson Sasumaa Aanesuto

Horutsuhauaa Robaato

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mundipharma AG

Original Assignee

Mundipharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1976-08-25

Filing date

1977-08-25

Publication date

1986-12-27

1977-08-25 Application filed by Mundipharma AG filed Critical Mundipharma AG

1978-04-14 Publication of JPS5341417A publication Critical patent/JPS5341417A/ja

1986-12-27 Publication of JPS6161818B2 publication Critical patent/JPS6161818B2/ja

Status Granted legal-status Critical Current

Links

239000000203 mixture Substances 0.000 claims description 118
239000006260 foam Substances 0.000 claims description 78
-1 poly(oxyethylene) Polymers 0.000 claims description 40
150000002191 fatty alcohols Chemical class 0.000 claims description 36
239000003380 propellant Substances 0.000 claims description 35
235000014113 dietary fatty acids Nutrition 0.000 claims description 32
239000000194 fatty acid Substances 0.000 claims description 32
229930195729 fatty acid Natural products 0.000 claims description 32
150000004665 fatty acids Chemical class 0.000 claims description 32
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 31
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 30
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
239000000645 desinfectant Substances 0.000 claims description 27
150000001875 compounds Chemical class 0.000 claims description 18
239000008194 pharmaceutical composition Substances 0.000 claims description 18
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 17
239000007788 liquid Substances 0.000 claims description 17
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 13
239000002736 nonionic surfactant Substances 0.000 claims description 13
230000000855 fungicidal effect Effects 0.000 claims description 11
239000000417 fungicide Substances 0.000 claims description 10
238000003756 stirring Methods 0.000 claims description 10
229910052709 silver Inorganic materials 0.000 claims description 9
239000004332 silver Substances 0.000 claims description 9
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 8
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 8
229920001993 poloxamer 188 Polymers 0.000 claims description 8
235000021355 Stearic acid Nutrition 0.000 claims description 7
235000011187 glycerol Nutrition 0.000 claims description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 7
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 7
229920005862 polyol Polymers 0.000 claims description 7
239000008117 stearic acid Substances 0.000 claims description 7
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical group II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
241001465754 Metazoa Species 0.000 claims description 6
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
229960000541 cetyl alcohol Drugs 0.000 claims description 6
239000008263 liquid aerosol Substances 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
229960003600 silver sulfadiazine Drugs 0.000 claims description 6
UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical group [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 claims description 6
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
239000004338 Dichlorodifluoromethane Substances 0.000 claims description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
239000004698 Polyethylene Substances 0.000 claims description 5
229920000153 Povidone-iodine Polymers 0.000 claims description 5
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical group [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 5
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 5
235000019404 dichlorodifluoromethane Nutrition 0.000 claims description 5
229940087091 dichlorotetrafluoroethane Drugs 0.000 claims description 5
229920000573 polyethylene Polymers 0.000 claims description 5
229960001621 povidone-iodine Drugs 0.000 claims description 5
150000002148 esters Chemical class 0.000 claims description 4
239000001282 iso-butane Substances 0.000 claims description 4
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 4
239000001294 propane Substances 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims description 4
VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
239000001569 carbon dioxide Substances 0.000 claims description 3
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 claims description 3
229940099364 dichlorofluoromethane Drugs 0.000 claims description 3
239000004615 ingredient Substances 0.000 claims description 3
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 3
TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical group NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
239000000872 buffer Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
229940091629 sulfamylon Drugs 0.000 claims description 2
125000004417 unsaturated alkyl group Chemical group 0.000 claims 4
UJPMYEOUBPIPHQ-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound CC(F)(F)F UJPMYEOUBPIPHQ-UHFFFAOYSA-N 0.000 claims 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
235000021314 Palmitic acid Nutrition 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
238000002844 melting Methods 0.000 claims 1
230000008018 melting Effects 0.000 claims 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
210000001519 tissue Anatomy 0.000 description 21
239000000243 solution Substances 0.000 description 18
239000002904 solvent Substances 0.000 description 18
239000007789 gas Substances 0.000 description 17
239000001257 hydrogen Substances 0.000 description 15
229910052739 hydrogen Inorganic materials 0.000 description 15
230000000844 anti-bacterial effect Effects 0.000 description 13
239000011159 matrix material Substances 0.000 description 13
210000004400 mucous membrane Anatomy 0.000 description 13
239000002798 polar solvent Substances 0.000 description 13
239000004480 active ingredient Substances 0.000 description 12
230000004888 barrier function Effects 0.000 description 12
239000012071 phase Substances 0.000 description 12
150000003839 salts Chemical class 0.000 description 12
238000005299 abrasion Methods 0.000 description 11
239000006185 dispersion Substances 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 11
238000007614 solvation Methods 0.000 description 11
238000004659 sterilization and disinfection Methods 0.000 description 10
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 9
208000014674 injury Diseases 0.000 description 9
229910052740 iodine Inorganic materials 0.000 description 9
239000011630 iodine Substances 0.000 description 9
239000000126 substance Substances 0.000 description 8
239000003242 anti bacterial agent Substances 0.000 description 7
229940088710 antibiotic agent Drugs 0.000 description 7
230000000249 desinfective effect Effects 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 7
238000011282 treatment Methods 0.000 description 7
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
230000003115 biocidal effect Effects 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000009826 distribution Methods 0.000 description 6
230000002070 germicidal effect Effects 0.000 description 6
150000003377 silicon compounds Chemical class 0.000 description 6
229910052717 sulfur Inorganic materials 0.000 description 6
239000011593 sulfur Substances 0.000 description 6
230000008733 trauma Effects 0.000 description 6
208000027418 Wounds and injury Diseases 0.000 description 5
239000004599 antimicrobial Substances 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
238000009835 boiling Methods 0.000 description 5
230000008859 change Effects 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
238000002803 maceration Methods 0.000 description 5
239000002674 ointment Substances 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
229940126575 aminoglycoside Drugs 0.000 description 4
239000003599 detergent Substances 0.000 description 4
239000004205 dimethyl polysiloxane Substances 0.000 description 4
235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
150000008282 halocarbons Chemical class 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
239000002245 particle Substances 0.000 description 4
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
239000007921 spray Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
230000002421 anti-septic effect Effects 0.000 description 3
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
150000002337 glycosamines Chemical class 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
150000002496 iodine Chemical class 0.000 description 3
230000007794 irritation Effects 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
230000005923 long-lasting effect Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
230000010287 polarization Effects 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
229940069328 povidone Drugs 0.000 description 3
238000001228 spectrum Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
VJYAJQFKKLYARJ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 VJYAJQFKKLYARJ-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
241000194032 Enterococcus faecalis Species 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
108010026389 Gramicidin Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000588915 Klebsiella aerogenes Species 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 2
229930182555 Penicillin Natural products 0.000 description 2
108010093965 Polymyxin B Proteins 0.000 description 2
241000588767 Proteus vulgaris Species 0.000 description 2
241000589516 Pseudomonas Species 0.000 description 2
MSXMXWJPFIDEMT-UHFFFAOYSA-N Streptidine Natural products NC(N)=NC1C(O)C(O)C(O)C(N=C(N)N)C1O MSXMXWJPFIDEMT-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
235000020661 alpha-linolenic acid Nutrition 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
239000003899 bactericide agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
238000011049 filling Methods 0.000 description 2
229960004905 gramicidin Drugs 0.000 description 2
ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
230000009931 harmful effect Effects 0.000 description 2
230000035876 healing Effects 0.000 description 2
239000011261 inert gas Chemical class 0.000 description 2
229960004488 linolenic acid Drugs 0.000 description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000005527 organic iodine compounds Chemical class 0.000 description 2
230000002688 persistence Effects 0.000 description 2
229940044519 poloxamer 188 Drugs 0.000 description 2
229960003548 polymyxin b sulfate Drugs 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
229940007042 proteus vulgaris Drugs 0.000 description 2
230000018528 secretion by tissue Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
150000003378 silver Chemical class 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
MSXMXWJPFIDEMT-FAEUDGQSSA-N streptidine Chemical compound NC(=N)N[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](NC(N)=N)[C@@H]1O MSXMXWJPFIDEMT-FAEUDGQSSA-N 0.000 description 2
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
229940029284 trichlorofluoromethane Drugs 0.000 description 2
238000009827 uniform distribution Methods 0.000 description 2
ZHIKHAVOCHJPNC-SQAHNGQVSA-N (2r,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(1r,2r,3s,4r,6s)-4,6-diamino-2,3-dihydroxycyclohexyl]oxyoxane-3,4-diol;undec-10-enoic acid Chemical compound OC(=O)CCCCCCCCC=C.N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N ZHIKHAVOCHJPNC-SQAHNGQVSA-N 0.000 description 1
VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
TUATYNXRYJTQTQ-BVRBKCERSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 TUATYNXRYJTQTQ-BVRBKCERSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
108010065839 Capreomycin Proteins 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
108010078777 Colistin Proteins 0.000 description 1
PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
101000868789 Drosophila melanogaster Carboxypeptidase D Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
239000004104 Oleandomycin Substances 0.000 description 1
RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000004100 Oxytetracycline Substances 0.000 description 1
241000228143 Penicillium Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
229940005553 analgesics and anesthetics Drugs 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
239000006265 aqueous foam Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical class C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229940064804 betadine Drugs 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229960002968 capreomycin sulfate Drugs 0.000 description 1
RTYJTGSCYUUYAL-YCAHSCEMSA-L carbenicillin disodium Chemical compound [Na+].[Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)C(C([O-])=O)C1=CC=CC=C1 RTYJTGSCYUUYAL-YCAHSCEMSA-L 0.000 description 1
229960005255 carbenicillin disodium Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229950004030 cefaloglycin Drugs 0.000 description 1
FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
229960000603 cefalotin Drugs 0.000 description 1
FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
229940106164 cephalexin Drugs 0.000 description 1
ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical group S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
VGEOUKPOQQEQSX-OALZAMAHSA-M cephapirin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CSC1=CC=NC=C1 VGEOUKPOQQEQSX-OALZAMAHSA-M 0.000 description 1
229940009063 cephapirin sodium Drugs 0.000 description 1
JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
238000004581 coalescence Methods 0.000 description 1
229960003346 colistin Drugs 0.000 description 1
238000002485 combustion reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000000039 congener Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
229960004060 dicloxacillin sodium Drugs 0.000 description 1
SIGZQNJITOWQEF-VICXVTCVSA-M dicloxacillin sodium monohydrate Chemical compound O.[Na+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl SIGZQNJITOWQEF-VICXVTCVSA-M 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
238000005187 foaming Methods 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
229960001235 gentian violet Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
229960004068 hexachlorophene Drugs 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
239000003906 humectant Substances 0.000 description 1
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229940035535 iodophors Drugs 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
229960002064 kanamycin sulfate Drugs 0.000 description 1
150000002596 lactones Chemical group 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229940051860 methacycline hydrochloride Drugs 0.000 description 1
MGFZNWDWOKASQZ-UMLIZJHQSA-M methicillin sodium Chemical compound [Na+].COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 MGFZNWDWOKASQZ-UMLIZJHQSA-M 0.000 description 1
229940019826 methicillin sodium Drugs 0.000 description 1
239000000693 micelle Substances 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
229960001775 nafcillin sodium Drugs 0.000 description 1
OCXSDHJRMYFTMA-KMFBOIRUSA-M nafcillin sodium monohydrate Chemical compound O.[Na+].C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C([O-])=O)=O)C(OCC)=CC=C21 OCXSDHJRMYFTMA-KMFBOIRUSA-M 0.000 description 1
239000005445 natural material Substances 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical class NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
235000019367 oleandomycin Nutrition 0.000 description 1
229960002351 oleandomycin Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
229960003994 oxacillin sodium Drugs 0.000 description 1
229960000625 oxytetracycline Drugs 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940056360 penicillin g Drugs 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
239000008255 pharmaceutical foam Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 1
229960004894 pheneticillin Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000001453 quaternary ammonium group Chemical group 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229940009188 silver Drugs 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
231100000075 skin burn Toxicity 0.000 description 1
VDUVBBMAXXHEQP-ZTRPPZFVSA-M sodium;(2s,6r)-3,3-dimethyl-6-[(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2[C@H](C(C)(C)SC21)C([O-])=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 VDUVBBMAXXHEQP-ZTRPPZFVSA-M 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
229960002673 sulfacetamide Drugs 0.000 description 1
SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
229960004306 sulfadiazine Drugs 0.000 description 1
FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical class NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
229960004818 sulfaphenazole Drugs 0.000 description 1
QWCJHSGMANYXCW-UHFFFAOYSA-N sulfaphenazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=NN1C1=CC=CC=C1 QWCJHSGMANYXCW-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229940104261 taurate Drugs 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
229940072172 tetracycline antibiotic Drugs 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
229940041677 topical spray Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Dispersion Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Materials For Medical Uses (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP10214377A 1976-08-25 1977-08-25 Production and use of sprayable foamed pasteurizing composition Granted JPS5341417A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US71765076A	1976-08-25	1976-08-25

Publications (2)

Publication Number	Publication Date
JPS5341417A JPS5341417A (en)	1978-04-14
JPS6161818B2 true JPS6161818B2 (no)	1986-12-27

Family

ID=24882914

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP10214377A Granted JPS5341417A (en)	1976-08-25	1977-08-25	Production and use of sprayable foamed pasteurizing composition

Country Status (23)

Country	Link
JP (1)	JPS5341417A (no)
AT (1)	AT362490B (no)
AU (1)	AU511270B2 (no)
BE (1)	BE855332A (no)
BR (1)	BR7705515A (no)
CA (1)	CA1095410A (no)
DE (1)	DE2736777A1 (no)
DK (1)	DK374477A (no)
ES (1)	ES459743A1 (no)
FI (1)	FI63669C (no)
FR (1)	FR2362621A1 (no)
GB (1)	GB1561423A (no)
IE (1)	IE45321B1 (no)
IL (1)	IL52045A (no)
IN (1)	IN145827B (no)
MX (1)	MX4782E (no)
NL (1)	NL7706203A (no)
NO (1)	NO145817C (no)
NZ (1)	NZ184060A (no)
PH (1)	PH16753A (no)
PT (1)	PT66534B (no)
SE (1)	SE412519B (no)
ZA (1)	ZA772946B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8315787D0 (en) *	1983-06-08	1983-07-13	Briggs J H	Coolant spray
US4534958A (en) *	1983-07-13	1985-08-13	Basf Wyandotte Corporation	Aerosol gel
EP0160051B1 (en) *	1983-10-24	1992-01-08	Lockley Services Pty. Ltd.	Foamable biocide composition
EP0406275A4 (en) *	1988-03-21	1992-05-06	Daratech Pty. Ltd.	Teat dip
IT1265647B1 (it) *	1992-11-18	1996-11-22	Farmin Srl	Composizione farmaceutiche topiche per le allergie respiratorie
DE19616573C2 (de) *	1996-04-25	1999-03-04	Pari Gmbh	Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
US20030082107A1 (en) *	1997-10-01	2003-05-01	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US8512718B2 (en)	2000-07-03	2013-08-20	Foamix Ltd.	Pharmaceutical composition for topical application
US7109241B1 (en)	2000-10-02	2006-09-19	Ecolab, Inc.	Antimicrobial compositions formulated for use in cold temperature conditions and methods of use thereof
DE10134786A1 (de) *	2001-07-17	2003-02-06	Beiersdorf Ag	Schäumbare Zubereitungen
IL152486A0 (en)	2002-10-25	2003-05-29	Meir Eini	Alcohol-free cosmetic and pharmaceutical foam carrier
US7700076B2 (en)	2002-10-25	2010-04-20	Foamix, Ltd.	Penetrating pharmaceutical foam
US8900554B2 (en)	2002-10-25	2014-12-02	Foamix Pharmaceuticals Ltd.	Foamable composition and uses thereof
US8119150B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Non-flammable insecticide composition and uses thereof
US8119109B2 (en)	2002-10-25	2012-02-21	Foamix Ltd.	Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en)	2002-10-25	2016-02-23	Foamix Pharmaceuticals Ltd.	Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en)	2002-10-25	2017-06-06	Foamix Pharmaceuticals Ltd.	Nonsteroidal immunomodulating kit and composition and uses thereof
US7820145B2 (en)	2003-08-04	2010-10-26	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en)	2003-08-04	2010-04-27	Foamix, Ltd.	Foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en)	2002-10-25	2008-06-12	Foamix Ltd.	Foam prepared from nanoemulsions and uses
US8486376B2 (en)	2002-10-25	2013-07-16	Foamix Ltd.	Moisturizing foam containing lanolin
NZ540166A (en)	2002-10-25	2007-06-29	Foamix Ltd	Cosmetic and pharmaceutical foam
US9211259B2 (en)	2002-11-29	2015-12-15	Foamix Pharmaceuticals Ltd.	Antibiotic kit and composition and uses thereof
US10117812B2 (en)	2002-10-25	2018-11-06	Foamix Pharmaceuticals Ltd.	Foamable composition combining a polar solvent and a hydrophobic carrier
EA009031B1 (ru) *	2003-01-24	2007-10-26	Стифел Рисерч Оустрэйлиа Пти Лтд.	Пена на основе фосфата клиндамицина
US7575739B2 (en)	2003-04-28	2009-08-18	Foamix Ltd.	Foamable iodine composition
US8486374B2 (en)	2003-08-04	2013-07-16	Foamix Ltd.	Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en)	2003-08-04	2014-08-05	Foamix Ltd.	Compositions with modulating agents
US9028852B2 (en) *	2004-09-07	2015-05-12	3M Innovative Properties Company	Cationic antiseptic compositions and methods of use
US20080260655A1 (en)	2006-11-14	2008-10-23	Dov Tamarkin	Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en)	2007-08-07	2014-01-28	Foamix Ltd.	Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en)	2007-11-30	2016-09-13	Foamix Pharmaceuticals Ltd.	Foam containing benzoyl peroxide
WO2009072007A2 (en)	2007-12-07	2009-06-11	Foamix Ltd.	Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8518376B2 (en)	2007-12-07	2013-08-27	Foamix Ltd.	Oil-based foamable carriers and formulations
WO2009090558A2 (en)	2008-01-14	2009-07-23	Foamix Ltd.	Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2010125470A2 (en)	2009-04-28	2010-11-04	Foamix Ltd.	Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en)	2009-07-29	2011-02-03	Foamix Ltd.	Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en)	2009-07-29	2011-02-03	Foamix Ltd.	Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2776471C (en)	2009-10-02	2019-02-12	Foamix Ltd.	Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en)	2009-10-02	2017-12-26	Foamix Pharmaceuticals Ltd.	Methods for accelerated return of skin integrity and for the treatment of impetigo
MX377365B (es)	2016-09-08	2025-03-10	Journey Medical Corp	Composiciones y métodos para tratar rosácea y acné.
US20240158596A1 (en) *	2022-11-07	2024-05-16	Critical Innovations Llc	Systems and methods relating to medical applications of inverse thermosensitive polymer foam formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR3068M (fr) *	1956-12-20	1965-01-18	Alexander Farkas	Médicament topique applicable notamment au traitement des blessures ouvertes et des brulures.
US2968628A (en) *	1958-10-17	1961-01-17	Shulton Inc	Propellant composition
FR1401540A (fr) *	1963-05-31	1965-06-04	Mediline Ag	Composition désodorisante et désinfectante à pulvériser
GB1121563A (en) *	1966-06-07	1968-07-31	Yardley And Company Ltd	Self-propelled homogeneous liquid compositions
US3584115A (en) *	1968-05-31	1971-06-08	Arthur Ira Gebhart	Method of applying visible aerosol compositions
US3639568A (en) *	1968-09-23	1972-02-01	Alberto Culver Co	Gas-releasable and foamable compositions
US3930000A (en) *	1971-06-16	1975-12-30	Univ Washington	Silver-zinc allantoinate compositions and method of killing bacteria and fungi therewith
US3770648A (en) *	1971-07-12	1973-11-06	Bristol Myers Co	Anhydrous aerosol foam
OA04325A (fr) *	1973-01-09	1980-01-15	Mundipharma Ag	Procédé de préparation de composés bis-phosphorylés d'anthraline.

1977
- 1977-05-06 IL IL52045A patent/IL52045A/xx unknown
- 1977-05-10 NZ NZ184060A patent/NZ184060A/xx unknown
- 1977-05-11 PT PT66534A patent/PT66534B/pt unknown
- 1977-05-17 ZA ZA00772946A patent/ZA772946B/xx unknown
- 1977-05-18 IN IN736/CAL/77A patent/IN145827B/en unknown
- 1977-05-23 FI FI771636A patent/FI63669C/fi not_active IP Right Cessation
- 1977-05-23 AU AU25379/77A patent/AU511270B2/en not_active Expired
- 1977-05-25 CA CA279,161A patent/CA1095410A/en not_active Expired
- 1977-06-02 BE BE178147A patent/BE855332A/xx not_active IP Right Cessation
- 1977-06-06 NL NL7706203A patent/NL7706203A/xx not_active Application Discontinuation
- 1977-06-07 PH PH19856A patent/PH16753A/en unknown
- 1977-06-14 ES ES459743A patent/ES459743A1/es not_active Expired
- 1977-06-23 SE SE7707332A patent/SE412519B/xx unknown
- 1977-07-18 FR FR7721993A patent/FR2362621A1/fr active Granted
- 1977-07-26 GB GB31282/77A patent/GB1561423A/en not_active Expired
- 1977-07-27 IE IE1570/77A patent/IE45321B1/en unknown
- 1977-08-05 AT AT577277A patent/AT362490B/de not_active IP Right Cessation
- 1977-08-16 DE DE19772736777 patent/DE2736777A1/de not_active Withdrawn
- 1977-08-17 MX MX776036U patent/MX4782E/es unknown
- 1977-08-18 NO NO772878A patent/NO145817C/no unknown
- 1977-08-18 BR BR7705515A patent/BR7705515A/pt unknown
- 1977-08-23 DK DK374477A patent/DK374477A/da not_active Application Discontinuation
- 1977-08-25 JP JP10214377A patent/JPS5341417A/ja active Granted

Also Published As

Publication number	Publication date
DE2736777A1 (de)	1978-03-09
ATA577277A (de)	1980-10-15
AT362490B (de)	1981-05-25
IE45321L (en)	1978-02-25
FI771636A (fi)	1978-02-26
NO145817B (no)	1982-03-01
PT66534A (fr)	1977-06-01
SE7707332L (sv)	1978-02-26
IN145827B (no)	1978-12-30
NO145817C (no)	1982-06-09
IL52045A0 (en)	1977-07-31
SE412519B (sv)	1980-03-10
IE45321B1 (en)	1982-07-28
BE855332A (fr)	1977-10-03
PH16753A (en)	1984-02-10
FI63669B (fi)	1983-04-29
JPS5341417A (en)	1978-04-14
IL52045A (en)	1979-12-30
NL7706203A (nl)	1978-02-28
ZA772946B (en)	1978-04-26
CA1095410A (en)	1981-02-10
DK374477A (da)	1978-02-26
BR7705515A (pt)	1978-04-25
PT66534B (fr)	1978-10-17
FR2362621A1 (fr)	1978-03-24
ES459743A1 (es)	1978-12-01
FI63669C (fi)	1983-08-10
NZ184060A (en)	1979-10-25
MX4782E (es)	1982-09-21
NO772878L (no)	1978-02-28
AU511270B2 (en)	1980-08-07
GB1561423A (en)	1980-02-20
AU2537977A (en)	1978-11-30
FR2362621B1 (no)	1980-04-04

Publication	Publication Date	Title
JPS6161818B2 (no)	1986-12-27
KR890001881B1 (ko)	1989-05-29	크림기제 조성물
US3751562A (en)	1973-08-07	Medicated gelled oils
Fox	1968	Silver sulfadiazine—a new topical therapy for pseudomonas in burns: therapy of pseudomonas infection in burns
ES2200008T3 (es)	2004-03-01	Formulacion espumable y espuma.
JP5634655B2 (ja)	2014-12-03	薬剤耐性生物の治療
JPH08501528A (ja)	1996-02-20	火傷用泡沫と搬送システム
JP4416844B2 (ja)	2010-02-17	架橋ポリビニルピロリドン−ヨウ素複合物及びその製造方法
WO1998044930A1 (en)	1998-10-15	Povidone iodine (pvp-i) alcohol gel antimicrobial pre-operative skin preparation
US20080020025A1 (en)	2008-01-24	Composition for wound care and method of using same
CN104582688A (zh)	2015-04-29	具有组织相容性的抗菌材料组合物及其用途
TW201216859A (en)	2012-05-01	Disinfectant and antiseptic formulation having reduced iodine content
RU2710019C2 (ru)	2019-12-24	Пенообразующие композиции и способы доставки активного агента в полость тела
Rodeheaver et al.	1976	Pharmacokinetics of a new skin wound cleanser
RU2233151C2 (ru)	2004-07-27	Применение тозилхлорамидов для лечения заболеваний кожи и слизистой оболочки
RU2080864C1 (ru)	1997-06-10	Средство для лечения гнойных ран
JPS61100256A (ja)	1986-05-19	沃素制御放出用製剤
WO2020136552A9 (en)	2021-08-05	Antimicrobial compositions with 1,2-alkanediols
WO2007143586A2 (en)	2007-12-13	Composition for wound care and method of using same
US4388302A (en)	1983-06-14	Coacervated iodine
US20230052601A1 (en)	2023-02-16	Halo active aromatic sulfonamide pharmaceutical compositions for internal use
WO2001000251A1 (en)	2001-01-04	Antiseptic and antimicrobial pharmaceutical preparation of feracrylum
RU2682454C1 (ru)	2019-03-20	Мазь для лечения термических ожогов и способ их лечения
KR100487103B1 (ko)	2005-05-04	은 화합물을 유효 성분으로 함유하는 피부 질환 치료용 제제
US20210290666A1 (en)	2021-09-23	ANTIMICROBIAL and ANTI-INFLAMMATORY COMPOSITION